Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EMBC
EMBC logo

EMBC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Embecta Corp (EMBC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
3.110
1 Day change
0.65%
52 Week Range
15.550
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Embecta Corp (EMBC) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant negative sentiment due to class action lawsuits, weak financial performance, and declining analyst ratings. Technical indicators suggest a bearish trend, and there are no positive proprietary trading signals or catalysts to support a buy decision.

Technical Analysis

The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. The RSI is neutral at 34.384, and the MACD histogram is slightly positive but contracting. Key support is at $3.052, and resistance is at $3.404. The stock has a 50% chance to decline further in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
6

Positive Catalysts

  • NULL identified. No positive trading signals or recent news to support a bullish outlook.

Neutral/Negative Catalysts

  • Multiple class action lawsuits alleging misleading financial disclosures and weaknesses in the U.S. pen needle market. Analysts have downgraded the stock and significantly reduced price targets. The stock has experienced a sharp decline in value, with no signs of recovery.

Financial Performance

No financial data available for the latest quarter. However, analysts have cited weak fiscal Q2 performance, declining revenue, and reduced profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have a negative outlook on the stock. BofA, Mizuho, and BTIG have downgraded the stock or reduced price targets significantly, citing weak financial performance, market share loss, and lack of growth prospects.

Wall Street analysts forecast EMBC stock price to rise
Analyst Rating
0
Wall Street analysts forecast EMBC stock price to rise
Buy
Hold
Sell
0
Current: 3.090
sliders
Low
0
Averages
0
High
0
0
Current: 3.090
sliders
Low
0
Averages
0
High
0
BofA
Travis Steed
Underperform
downgrade
$11 -> $3
AI Analysis
2026-05-18
Reason
BofA
Travis Steed
Price Target
$11 -> $3
AI Analysis
2026-05-18
downgrade
Underperform
Reason
BofA analyst Travis Steed lowered the firm's price target on Embecta to $3 from $11 and keeps an Underperform rating on the shares. After having hosted 34 medtech companies last week in Las Vegas, the firm updated several price targets for "the new reality of medtech valuations" in a year of few product cycles, ACA and utilization worries, inflation kicking up post-war, and "data centers over healthcare," the analyst tells investors.
Mizuho
Neutral
downgrade
$12 -> $5
2026-05-06
Reason
Mizuho
Price Target
$12 -> $5
2026-05-06
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Embecta to $5 from $12 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EMBC
Unlock Now

People Also Watch